Catalog Advanced Search

Search by Category
Search by Format
Sort By
Search by Type
Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Product not yet rated Contains 2 Component(s)

    Webinar hosted by the Clinical Practice Special Interest Group on Thursday, September 15, 2022.

    Ascites is a common complication and often the first sign of decompensation in patients with End-Stage Liver Disease. Management of ascites is often fraught with complex challenges including electrolyte imbalances, renal failure, hepatic encephalopathy, and significant utilization of resources. A proportion of the patients do not respond to conventional diuretic therapy (refractory ascites) or develop significant side effects that limit the diuretics' optimal dosing, leading to suboptimal control of ascites ( intractable ascites). This webinar will review recent advances in managing refractory/intractable ascites.

  • Contains 2 Component(s)

    Webinar hosted by the Clinical Practice Special Interest Group on Thursday, July 14, 2022.

    Management of autoimmune hepatitis is often quite complex, especially for those not achieving remission with conventional immunosuppression. This webinar aims to review current and upcoming pharmacological treatment options in the management of these special groups of patients.

  • Contains 8 Component(s)

    Recordings from the AASLD/EASL NAFLD Nomenclature Consensus Conference can be accessed here. The conference took place July 8-9, 2022 in Chicago, IL and virtually.

    Recordings from the AASLD/EASL NAFLD Nomenclature Consensus Conference can be accessed here. The conference took place July 8-9, 2022 in Chicago, IL and virtually.

  • Product not yet rated Contains 7 Component(s)

    The purpose of the AASLD/EASL HBV Endpoints Conference is to bring together the academic, regulatory, pharmaceutical communities and patients’ advocacy groups to discuss therapeutic endpoints, trial designs appropriate patient populations and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D.

    The purpose of the AASLD/EASL HBV Endpoints Conference is to bring together the academic, regulatory, pharmaceutical communities and patients’ advocacy groups to discuss therapeutic endpoints, trial designs appropriate patient populations and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D. The HBV therapeutic field is at a crossroads with many different approaches being considered but numerous regulatory issues, trial design issues and safety issues need to be addressed. This meeting will be unique in that it will bring all the important and relevant parties to the table to discuss these critical issues that will need to be resolved before substantial progress can be made in delivering the next generation of therapeutic agents to affected individuals with chronic hepatitis B and D.

  • Product not yet rated Contains 2 Component(s)

    Joint webinar organized by the AASLD and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN).

    There has been a recent worldwide identification, first from the United Kingdom then globally including the United States, of an unidentified pathogen leading to a plausible increase in cases of severe acute hepatitis in children. Some of these cases have been linked to Adenovirus Type 41, but many questions remain. Of the important etiopathogenesis questions the following will be posed, specifically: 1)Are these cases an increase over prior years? 2) Are these cases all related to the same pathogen? 3)Is there any possible connection to SARSCov2 past infections?

    These and other similarly topical, time-sensitive, and relevant questions will be addressed by this joint webinar organized by the AASLD and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN).

  • Product not yet rated Contains 1 Component(s)

    Webinar hosted by the AASLD COVID-19 Task Force's Clinical Oversight and Education Subcommittee on Wednesday, April 13.

    The AASLD COVID-19 Task Force's Clinical Oversight and Education Subcommittee presents a new installment in its popular COVID-19 and the Liver webinar series. We will begin by covering the therapeutics and pathways to treat outpatients with COVID-19. This will be followed by an overview of the epidemiology of transplant donors and recipients with COVID-19 and an open discussion with a distinguished panel of experts. The expert roundtable discussion will cover the difficult issues surrounding the management of liver transplant donors and recipients who test positive for SARS-CoV-2. Are we using enough of these controversial organs or are we taking unreasonable risks? What really is the risk of donor to recipient disease transmission? What other issues do we need to consider before we accept a SARS-CoV-2 positive donor or recipient? Bring your questions and challenge the panel or just listen in to this exciting and informative webinar.

  • Contains 2 Component(s) Recorded On: 03/15/2022

    Webinar hosted by the Portal Hypertension: Clinical and Experimental Special Interest Group on Tuesday, March 15, 2022.

    This webinar will address endovascular management of portal hypertensive complications using TIPS. Speakers will assess evidence for the use of TIPS in the setting of portal and mesenteric vein thromboses and how this may impact portal HTN, survival, as well as transplant outcomes. Speakers will also discuss the standard and emerging indications for TIPS as well as future directions for TIPS management in portal HTN.

    Virginia Hernandez-Gea

    Virginia Hernández-Gea, MD, PhD is a interventional hepatologist at the liver unit at hospital clinic. She is fully dedicated to the management of patients with portal hypertension and vascular liver diseases as well as conducting liver catheterization procedures including TIPS. She also runs a translational laboratory focused on the understanding of the role of the liver endothelium in liver diseases.

    Dr. Hernández-Gea is a member of the EASL Governing Board and author of more than 120 publications. She has serves as editorial boar member of Hepatology and Liver international. She is currently member of the Portal Hypertension Special Interest Group for the American Association for the Study of Liver Diseases (AASLD), Secretary of VALDIG  (Vascular Liver Disease Interest Group) and faculty of Baveno. As an active teacher and educator, she has directed 5 doctoral thesis and is assistant professor at the university of Barcelona.

    Riad Salem

    Riad Salem, MD, MBA is Professor of Radiology, Surgery and Medicine, Vice-Chair, Image-Guided Therapy and Section Chief, Interventional Radiology in the Department of Radiology at Northwestern University in Chicago. His areas of interest include the use of image-guided techniques for the treatment of liver cancer including chemoembolisation, bland embolization and radioembolisation. He is a graduate of McGill University in Montreal, where he was recipient of the Wood Gold Medal and J Francis Award in Internal Medicine. He then completed his residency in Washington DC, a fellowship in interventional radiology (University of Pennsylvania), as well as a Master’s in Business Administration (Finance).

    Dr. Salem is a member of Alpha Omega Alpha medical honor society and a Fellow of the Society of Interventional Radiology. He has delivered >800 lectures nationally and internationally, and written extensively on the subject of interventional oncology and portal hypertension (TIPS), with over 370 publications, 28000 citations, and an h index of 92. His current research focus on: 1) hepatocellular carcinoma advances in minimally invasive therapies, 2) imaging methodologies following locoregional treatment, and 3) treatment of portal vein thrombosis in cirrhotics and non-cirrhotic using novel TIPS techniques, with conversion of untransplantable patients to transplant candidacy. He serves as PI of two, international, randomized phase III trials involving sorafenib +/- Y90 in HCC (STOP-HCC) and chemotherapy +/- Y90 in CRC (EPOCH); EPOCH was the first large-scale RCT to meet its endpoints in the field of interventional oncology. He was also lead investigator in LEGACY, the pivotal trial that lead to the FDA’s first PMA device approval.

    Elizabeth Verna (Moderator)

    Elizabeth Verna, MD, MS is an Associate Professor of Medicine in the Center for Liver Disease and Transplantation and Division of Digestive and Liver Diseases at Columbia University, where she practices as transplant hepatologist. In addition, Dr. Verna has an active clinical research program in end-stage liver disease and liver transplantation and is the Director of Clinical Research for the Columbia University Transplant Clinical Research Center.

  • Contains 2 Component(s) Recorded On: 02/23/2022

    Webinar hosted by the Inclusion and Diversity Committee on Wednesday, February 23.

    The purpose of this webinar is to discuss action items for the AASLD and academic institutions. These action items will focus on efforts to improve diversity, equity and inclusion in all aspects of the hepatology continuum, including the hepatology work force as well as racial disparities in hepatology care. The webinar will include a formal 10-minute overview of the concepts of diversity, equity and inclusion and another 10-minute formal presentation on proposed future directions outlined in the white paper. There will then be a 20-minute moderated discussion between panelist discussing perceived and actual barriers to these action items. The webinar will conclude with a 10-minute question and answer portion involving all faculty.

    Be sure to check out the additional resources in the Handouts section.

    Miguel H. Malespin

    Miguel H. Malespin M.D. is a transplant hepatologist at Tampa General Hospital and associate professor for the University of South Florida College of Medicine. He earned his medical degree at Ponce Health Sciences University in Puerto Rico. Dr. Malespin continued his training in internal medicine and gastroenterology at the University of Illinois at Chicago. He then completed a fellowship in transplant hepatology at Loyola University Medical Center. His areas of clinical and research interest include non-alcoholic fatty liver disease, viral hepatitis, and health disparities. He is an active member of the AGA and AASLD serving in multiple roles and committees.

    Carla W. Brady

    Carla Brady, MD, MHS, FAASLD is an Associate Professor in the Division of Gastroenterology at Duke University Medical Center, having been a faculty member within the division since 2006. She is a transplant hepatologist and has a particular interest in liver disease and liver transplantation from a women's health perspective. Dr. Brady is the author of manuscripts on and has given talks locally, regionally, and nationally on liver disease in pregnancy, pregnancy in transplant patients, liver disease and liver transplantation in menopausal women, and disparities in liver disease care. As an active member of the American Association for the Study of Liver Diseases (AASLD), she has served on its Scientific Program Committee and Nominating Committee. She has also served as chair of the AASLD Program Evaluation Committee and as chair of the AASLD Inclusion and Diversity Committee. Locally, she has served as an elected member of the Executive Committee of the Academic Council of Duke University, a steering committee member for the Duke University Academic Council Diversity Task Force and as a co-chair of its subcommittee on Best Practices in Faculty and Administrative Diversity. 

    Lauren D. Nephew (Moderator)

    Lauren D. Nephew, MD, MA, MSCE is Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at Indiana University School of Medicine.  Her research interests include understanding barriers to liver transplantation for vulnerable populations, disparities in care of patients with hepatocellular carcinoma, and the impact of the social and structural determinants of health on the outcomes of patients with liver disease. Dr. Nephew’s clinical work focuses on both decompensated liver disease patients being evaluated for liver transplantation as well as patients with chronic liver disease.  She is the chair of the Intersociety Group on Diversity and the chair of the AASLD Inclusion and Diversity Committee.

    Dr. Nephew attended medical school at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.  She completed residency at Massachusetts General Hospital and Gastroenterology and Liver Transplantation Fellowships at the University of Pennsylvania. While at Case Western Reserve University, Dr. Nephew completed a Masters program in Clinical Bioethics.   While at the University of Pennsylvania, Dr. Nephew completed a Masters of Science in Clinical Epidemiology.  Dr. Nephew is a health equity champion, wife, and mother of two. 

    Naudia L. Jonassaint

    Naudia L. Jonassaint, MD, MHS currently is an Associate Professor of Medicine and Surgery at the University of Pittsburgh School of Medicine. She is currently serving as the Vice Chair of the Diversity, Equity and Inclusion in the Department of Medicine and the Associate Dean of Clinical Affairs in School of Medicine. Dr. Jonassaint has a specific interest in disparate outcomes in liver disease and is also uniquely interested in diversity and inclusion in academic training.

    Dr. Jonassaint is currently serving on the Finance Committee for the American Association for the Study of Liver Diseases (AASLD) as well as serving on the editorial board for Liver Transplantation. Her collaborative research focuses the optimization of care for pre-transplant liver patients including transplant selection in addition to a focus on disparities in liver transplant outcomes. As an active teacher and educator, she has mentored many undergraduate, graduate and medical students as well as junior faculty and staff at the University of Pittsburgh and beyond.  

    Sonali Paul

    Sonali Paul is a transplant hepatologist and Assistant Professor of Medicine at the University of Chicago. She is also the director of the Metabolic and Fatty Liver clinic. She has an interest in non-alcoholic fatty liver disease, obesity medicine, organ allocation, health disparities, and shared decision making between patients and providers. She received an MD from Tufts University School of Medicine. She completed her internal medicine residency at Massachusetts General Hospital and returned to Tufts for her fellowship training in gastroenterology. She also earned an MS in clinical and translational science from the Sackler School of Graduate Biomedical Sciences at Tufts University. She completed an advanced hepatology fellowship at Massachusetts General Hospital in 2016 and joined the University of Chicago faculty shortly thereafter. 

    Laurie D. DeLeve

    Laurie D. DeLeve, MD, PhD, FAASLD has been on the faculty at the University of Southern California in Los Angeles since 1990 and is Professor of Medicine and Vice Chair for Scientific Affairs in the Department of Medicine at the Keck School of Medicine. She received her MD at the Erasmus University of Rotterdam in the Netherlands and her PhD at the University of Toronto in Canada. She did her training in Internal Medicine at the University of Michigan in Ann Arbor, followed by a fellowship in Gastroenterology/Hepatology at UCLA. Dr. DeLeve is a physician-scientist and is involved in patient care, basic research, and education of medical student, residents, and Fellows.

    Dr DeLeve’s NIH-funded research has focused on the biology and pathobiology of liver sinusoidal endothelial cells (LSECs). Early work from her laboratory demonstrated that LSECs were the initial target in sinusoidal obstruction syndrome and these studies provided significant insight into the mechanisms of this syndrome. Subsequent research examined the role of LSECs in other forms of liver injury. Dr DeLeve’s lab demonstrated that LSECs maintain hepatic stellate cell quiescence, that LSEC capillarization prior to fibrosis is permissive for hepatic stellate cell activation and why that is so.  In recent years, Dr. DeLeve’s lab was the first to identify resident and bone marrow sinusoidal endothelial cell progenitor cells, so-called bone marrow sprocs. Her laboratory has examined the role of bone marrow sprocs in acute and chronic liver injury.

  • Contains 34 Component(s), Includes Credits Recorded On: 02/21/2022

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    DESCRIPTION
    The overall goal is to improve patient care by increasing learner competence and confidence in assessment and management of patients with alcohol-associated liver disease. The current content is geared towards increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved because of the improvements in more providers understanding these key components in the management and care of patients with alcohol-associated liver disease. 

    Improving patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with alcohol-associated liver disease.

    KEY TOPIC AREAS
    Epidemiology and Disease Burden [12 minutes]
    Clinical Presentation of Alcohol-associated Liver Disease [15 minutes]
    Systemic Concomitant Manifestations [17 minutes]
    Diagnosis of Alcohol-associated Liver Disease [20 minutes]
    Diagnosis and Management of Alcohol Use Disorder [24 minutes]
    Current Medical Treatment Options [24 minutes]
    Liver Transplantation [25 minutes]
    Integrated Care Model to Treat Dual Pathology [23 minutes]
    Pathogenesis and Emerging Therapies [20 minutes]
    Prevention and Public Health Measure [16 minutes]

    Release date: February 21, 2022
    Expiration date: February 20, 2025
    Time to complete each module: 30 minutes

    CREDITS OFFERED
    Continuing Medical Education (CME): For a maximum of 5.00 AMA PRA Category 1 Credits™  
    Continuing Education (CE): For a maximum of 5.00 Contact Hour 
    You may only earn one Continuing Education Credit type - either CME or CE

    Maintenance of Certification (MOC): For a maximum of 5.00 MOC Points

    COMPONENTS Online presentations comprised of:
    -10 online interactive, narrated modules 10 to 25 minutes in length
    -Pre- and post-test questions for each module [5-10 minutes per module]
    -Evaluation for CME or CE credit offering [5-10 minutes]

    DIRECTIONS
    Click "Register" to activate the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2022 AASLD. 

    CONTACT INFORMATION 
    For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    After the completion of this course, the learner will be able to:

    • Identify alcohol associated liver disease
    • Apply diagnostic tests appropriately to characterize the disease severity
    • Discuss important counseling for long term success
    • Recognize treatment/referral priorities
    • Identify first line therapies, ongoing clinical trials and follow up to improve long term outcomes

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 5.00 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 5.00 MOC Points
    Continuing Education (CE): For a maximum of 5.00 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS  
    Continuing Medical Education (CME)  The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 5.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 5.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS 
    Physicians and other health care professionals for a maximum of 5.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by February 20, 2025

    CLAIMING CE CREDITS
    Nurses for a maximum of 5.00 contact hours for this enduring continuing education material must be completed by February 20, 2025

    CLAIMING ABIM MOC POINTS  
    Physicians seeking ABIM MOC credit must complete the enduring material by February 20, 2025. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through March 2025 for individuals who successfully complete MOC.

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-tests

                 o    Watch video presentations

                 o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing  score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning. The faculty, organizers and reviewers have reported the following disclosures:

    Juan P. Arab, MD
    Faculty
    Nothing to Disclose

    Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD
    Faculty
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Durect Corporation, TwoXar, Surrozen

    Gene Y. Im, MD
    Faculty
    Nothing to disclose

    Michael R. Lucey, MD, FAASLD
    Faculty
    Research Grants: Abbvie; NIAAA; PharmaSolutions; Intercept Pharma; Exact Sciences
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of Educational Presentations: Novartis 

    Lorenzo Leggio, MD, PhD
    Faculty
    Intellectual Property Rights (Patents, Royalties, Licensing fees): Royalties for textbook edited by Routledge

    Craig J. McClain, MD, FAASLD
    Faculty
    Research Grants: NIH, VA, GenFit, Target NASH, Diapharma, Gilead, Intercept, Novartis
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: US Federal Trade Commission

    Ashwani K. Singal, MD, MS, FACG, FAASLD
    Faculty
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: CLD Foundation, Medscape Gastroenterology, Up-To-Date.
    Research Grants: American College of Gastroenterology, National Institute of Alcohol Abuse and Alcoholism, National Institute of Digestive Diseases Diabetes and Kidney Diseases, GiLead

    Gerald (Scott) Winder, MD
    Faculty
    Nothing to disclose

    Gyongyi Szabo, MD, PhD, FAASLD
    Faculty
    Research Grants: NIH-NIAAA, Gilead
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: AASLD, Alinylam Pharma, Intercept, Novartis, Allergan, Glympse Bio, Generon

    Lauren D. Nephew, MD, MSCE
    Faculty
    Nothing to disclose

    Amanda J. Chaney, DNP, APRN, FNP-BC
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Royalties: Springer Publishing-Author 

    Rena Fox, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Grant/Research Support: Gilead Sciences

    Sonal Kumar, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead Sciences, Intercept and AbbVie 
    Speaker's Bureau: Gilead Sciences and AbbVie
    Grant/Research Support: Gilead Sciences, AbbVie and Intercept

    Adam Mikolajczyk, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    April G. Morris, FNP
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Speaker's Bureau: Gilead, AbbVie, Intercept Pharmaceuticals
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: AbbVie

    Paul Pockros, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Amol Rangnekar, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Raj Vuppalanchi, MD, FAASLD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance
    Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Susan Zapatka, DNP 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Dominique Clayton 
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support: No commercial support was received for this enduring material activity.

  • Product not yet rated Contains 2 Component(s) Recorded On: 02/08/2022

    Webinar hosted by the Membership and Mentorship Committee on Tuesday, February 8, 2022.

    This webinar, sponsored by the AASLD Membership and Mentorship Committee, will consist of three lectures from three mid-career faculty who have directly benefited from mentoring to achieve career success. As part of this educational webinar, the attendee will learn how the proper mentor can help a mentee attain their career goals while maintaining work-life balance. The attendee will also learn the art of menteering, to gain the most out of their relationship with their mentor. Finally, this webinar will introduce attendees to the new AASLD pilot program to bring potential mentees and mentors together in a virtual format.

    Vinay Sundaram

    Vinay Sundaram, MD, MSc is currently an Associate Professor of medicine and Director of Hepatology Outcomes Research at Cedars-Sinai Medical Center. He completed medical school at NYU School of Medicine, followed by a residency at the University of Virginia, gastroenterology fellowship at the University of Pittsburgh, and a transplant hepatology fellowship at Beth Israel Deaconess Medical Center.

    Dr. Sundaram has published more than 100 manuscripts including first authored papers in Gastroenterology, HEPATOLOGY, Journal of Hepatology and Liver Transplantation. He currently serves on the AASLD Acute on Chronic Liver Failure Special Interest Group’s steering committee and is the current chair of the AASLD Membership and Mentorship Committee. He is also on the editorial boards of HEPATOLOGY, American Journal of Gastroenterology and Hepatology Communications and previously served as on the UNOS membership and professional standards committee.

    Elliot B. Tapper

    Elliot Tapper, MD is Assistant Professor of Medicine at the University of Michigan Health System. Dr. Tapper’s research aims to improve the outcomes, quality of life and freedom from adverse events for patients with cirrhosis. His efforts focus on delineating quality indicators and developing interventions for the management and prevention of cirrhotic complications. His work on patient-centered, cost-effective diagnostic strategies for elevated liver enzymes have been published in journals including the American Journal of Gastroenterology, Journal of Hepatology, JAMA Internal Medicine, and the New England Journal of Medicine.

    Jennifer A. Flemming

    Jennifer A Flemming, MD, FRCPC, MAS is an ICES Scientist and Associate Professor of Medicine and Public Health Sciences for the Division of Gastroenterology at Queen’s University in Ontario Canada. She has advanced clinical training in hepatology and liver transplantation in addition to a master’s degree in clinical research from the University of California San Francisco. She is a clinician scientist who runs a research program which leverages the administrative healthcare databases in Ontario held at ICES to perform population based epidemiologic research in patients with chronic liver diseases, cirrhosis, and primary liver cancer with a special focus on underrepresented populations such as women and immigrants/refugees.

    Dr. Flemming is currently a member of the AASLD Women’s Initiatives Committee, Chair of the Guidelines Committee for the Canadian Association for the Study of Liver Disease (CASL) and a member of the CASL Equity and Diversity Committee. Her research program has been supported by the AASLD Foundation, the American Gastroenterological Association (AGA) and the Canadian Donation and Transplantation Research Program. She was the recipient of the 2021 CASL Research Excellence Award and has authored over forty peer-reviewed publications in leading journals such as Gastroenterology, Hepatology, and Lancet Gastroenterology and Hepatology. She is the incoming site director for ICES-Queen’s, a not-for-profit research institute encompassing a community of research, data and clinical experts, and a secure and accessible array of Ontario's health-related data. As an active teacher and educator, she has mentored over twenty-five trainees from undergraduate, to medical, Masters’ and PhD students in Public Health Sciences, clinical residents/fellows, and faculty at the Assistant Professor rank from Queen’s University as well as other institutions in the U.S. and Canada.

    Enis Kostallari (Moderator)

    Enis Kostallari, PhD is an Associate Consultant in the Division of Gastroenterology and Hepatology, an Assistant Professor of Medicine and an Assistant Professor of Biochemistry and Molecular Biology at Mayo Clinic. Dr. Kostallari’s research focuses on the pathobiology of non-parenchymal cells in liver fibrosis. More specifically, she investigates the intracellular mechanisms in the hepatic stellate cells which lead to the release of fibrogenic extracellular vesicles and ultimately liver fibrosis. In the past two years, Dr. Kostallari’s studies have been published in major journals such as Journal of Hepatology and Hepatology where she was the lead principal investigator and co-principal investigator, respectively.

    In addition to her science, Dr. Kostallari serves as a peer-reviewer for major journals, such as HepatologyJournal of HepatologyGastroenterologyJournal of Clinical InvestigationEMBO, and others, and is currently a guest editor for Frontiers in Molecular Biosciences. She has been an external reviewer for grant proposals in Belgium and France and is currently a writer for the Hepatology Highlights section in the Hepatology journal. She is a steering committee member of the AASLD Liver Fibrosis special interest group and a committee member of the Membership and Mentorship Committee. At Mayo Clinic, Dr. Kostallari is the chair of the Extracellular Vesicle interest group and a course instructor. As an active mentor, during her career she has supervised several trainees, from high school to undergraduate, medical, Masters’, PhD students, postdoctoral fellows and visiting scientists from institutions in the U.S. and overseas.